Obstructive Sleep Apnea of ChildNCT05154214
Surgical Treatment of Children With OSA and Small Tonsils or Down Syndrome
An observational study of Obstructive Sleep Apnea of Child, run by Oregon Health and Science University at 1 site in United States.
Trial summary
The purpose of this study is to prospectively compare the effectiveness of a novel personalized approach to the surgical treatment of obstructive sleep apnea (OSA) in children, drug induced sleep endoscopy (DISE) directed surgery versus the standard adenotonsillectomy (AT). Read more about this study
- Who is it for?
- Ages 2 to 18 years
- Conditions the study is for
- Obstructive Sleep Apnea of Child
- What is being tested?
- Adenotonsillectomy and Drug-induced sleep endoscopy directed surgery
- Type of treatment
- Surgery or procedure
- How many people
- 30 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Nov 2021to 11 Oct 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 2 to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Participants will be recruited from the Oregon Health and Science University pediatric otolaryngology clinic and from the pediatric sleep medicine clinic.
Who may be able to join
- Moderate OSA (oAHI ≥ 5),
- Clinically small tonsils (Brodsky score 1+ or 2+) AND/OR Down syndrome
- Desiring surgical treatment.
- English or Spanish speaking
Who cannot join
- Non-Down Syndrome neuromuscular disorder, craniofacial anomaly, genetic abnormality, subglottic or tracheal stenosis, tracheostomy dependence.
Trial locations and contacts
1 site in 1 country.
United States1 site
Oregon Health and Science University
Portland, Oregon, 97239
About this study
Official title: Prospective Study of Surgical Treatment of Children With Obstructive Sleep Apnea and Small Tonsils or Down Syndrome
The purpose of this study is to prospectively compare the effectiveness of a novel personalized approach to the surgical treatment of obstructive sleep apnea (OSA) in children, drug induced sleep endoscopy (DISE) directed surgery versus the standard adenotonsillectomy (AT). This will also serve to test the feasibility of recruiting families for a future randomized protocol comparing the same surgical techniques. It is the investigators' central hypothesis that a personalized DISE-directed surgical approach that uses existing procedures to address the specific fixed and dynamic anatomic features causing obstruction (ie, anatomic endotypes) in each child with small tonsils or Down syndrome will be superior to the currently recommended standard first line approach of AT. This novel approach may improve OSA outcomes and reduce the burden of unnecessary AT or secondary surgery for persistent OSA after an ineffective AT. To test this hypothesis, the investigators will study children aged 2 to 18 years with clinically small tonsils (Brodsky score 1+ or 2+ on a scale 1+ to 4+) OR Down syndrome.
Read the detailed description
Obstructive sleep apnea (OSA) is defined as repetitive obstruction of the upper airway during sleep and has been estimated to affect 1-6% of the general pediatric population. Untreated OSA in children has been associated with childhood hypertension, autonomic dysfunction, attention-deficit/hyperactivity disorder, neurobehavioral impairment, and poor quality of life. These sequelae contribute to a 226% increase in health care utilization among children with OSA compared to controls, primarily in the form of increased hospitalizations, emergency department visits, and medication use. Adenotonsillar hypertrophy is considered the most common risk factor for OSA in children, and adenotonsillectomy (AT) is the first line treatment.
Although AT is the recommended first line treatment for pediatric OSA in treatment guidelines, multiple studies have demonstrated that AT is not always curative, with estimates of persistent OSA after AT ranging from 25 to 75%. Many risk factors for AT failure have been reported, but the impact of tonsil size on AT outcome remains a controversial topic. Not every child with enlarged tonsils will have OSA, and conversely, there are many children with proven OSA who do not have clinically large tonsils or adenoids. The prevalence of small tonsils (1+ or 2+ on Brodsky tonsil scoring scale of 1+ to 4+) has been reported to be 67-70% among children with symptoms of OSA presenting to either the emergency department or a pediatric pulmonology clinic. Clinic assessment of tonsil size during an awake examination has not consistently correlated with either baseline disease severity or response to AT. The outcome of AT in children with small tonsils (Brodsky 1+ or 2+) remains unknown and clinical decisions in children with small tonsils are not evidence-based.
Patients with Down Syndrome have a higher incidence of OSA than the general pediatric population, with rates of 30-60%, resulting in increased morbidity and decreased quality of life for affected individuals. Children with Down Syndrome often undergo T\&A for obstructive sleep apnea; however 30-50% will have persistent obstructive sleep patterns requiring continuous positive pressure airway support (CPAP) or tracheotomy. Persistent obstruction is attributed to anatomic and physiologic differences in this population, including reduced muscular tone, macroglossia, maxillary hypoplasia, and lingual tonsil hypertrophy.
Drug-induced sleep endoscopy (DISE) enables direct observation of the sites and patterns of obstruction during sedated sleep. DISE increasingly helps guide surgical decision-making in adult OSA, and the investigators hypothesize DISE can guide surgical decisions in pediatric OSA and improve outcomes. Towards that end, the study team has developed and validated the DISE Rating Scale in children. Furthermore, the investigators have demonstrated DISE ratings of adenotonsillar obstruction during sedated sleep are strongly associated with both OSA severity and response to AT, unlike clinic assessments of tonsil size. This preliminary data and others' studies have identified non-adenotonsillar obstruction can also occur at the nose, palate, base of tongue, and larynx. DISE findings in surgically naïve children and the outcomes of procedures based on those findings have been reported in mostly small observational case series. The surgical plan may be modified from the standard AT in up to 77% of children based on DISE findings. These alternative procedures can be less invasive (e.g., only isolated adenoidectomy or isolated tonsillectomy) or include procedures to address other anatomic sites in addition to or instead of the tonsils and adenoids. The most commonly reported non-adenotonsillar sites of obstruction are the nose, velopharynx (soft palate), tongue base, and the larynx. DISE-directed surgery at these sites may improve pediatric OSA outcomes, but existing studies are small, uncontrolled case series in heterogeneous study populations. There are no trials directly comparing AT and DISE-directed surgery in the common scenario of surgically naïve children with small tonsils. This study will inform a future randomized trial that has the potential to change the paradigm of treating OSA in children with small tonsils or Down syndrome, thereby improving outcomes, and reducing inappropriate AT and need for secondary sleep surgery.
- Conditions
- Obstructive Sleep Apnea of Child
- Being tested
- Adenotonsillectomy, Drug-induced sleep endoscopy directed surgery
- Keywords
- Adenotonsillectomy, Drug-induced sleep endoscopy, pediatric, otolaryngology, OSA, sleep apnea, Down Syndrome
- Medical subject headings
- Sleep Apnea Syndromes, Down Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
AdenotonsillectomyProcedure or surgery
Removal of tonsils and adenoids
Drug-induced sleep endoscopy directed surgeryProcedure or surgery
Surgeries selected based on direct visualization of airway collapse using endoscopy during drug-induced sleep
| Study group | Role | What they receive |
|---|---|---|
| Adenotonsillectomy | Excision of the palatine tonsils and excision or ablation of the adenoids by each individual surgeon's preferred techniques. Receives: Procedure: Adenotonsillectomy | |
| Drug-induced sleep endoscopy directed surgery (DISE) | DISE will be performed by the surgeon performing the surgical intervention. The DISE Rating Scale assesses the degree of maximal closure or obstruction at six locations in the upper airway: the nose, nasopharynx (adenoids), velopharynx (soft palate), oropharynx (tonsils), tongue base (tongue, lingual tonsils), and larynx (epiglottis, arytenoids). The degree of obstruction is scored on a 3-point rating scale as none (0), partial (+1), or complete (+2) at each anatomic site. The rating at each anatomic level can be summed into a DISE Rating Scale total. The actual surgery performed will determine which established surgical treatments will be used based on the results of the DISE. Receives: Procedure: Drug-induced sleep endoscopy directed surgery |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Pediatric Quality of Life (PedsQL), a generic quality of life scale
Parent and child-reported surveys, higher scores indicate better quality of life, mean scores 0-100
Measured: 6 months post-surgery
Parent-reported ease of participation
Parent-reported survey or parent interview
Measured: 6 months post-surgery
Parent-reported barriers to recruitment
Parent-reported survey or parent interview
Measured: Initial visit
Change in Obstructive Sleep Apnea -18 (OSA-18): disease-specific quality of life survey
Parent-reported survey, higher scores mean higher disease burden, scores from 18-126
Measured: 6 months post-surgery
Parent-reported barriers to recruitment
Parent-reported survey or parent interview
Measured: 6 months post-surgery
Secondary outcomes (8)
Change in Obstructive Apnea-Hypopnea Index (oAHI)
As measured in clinical polysomnography (PSG)
Measured: 6 months post-surgery
Change in Total Apnea-Hypopnea Index
As measured in clinical polysomnography (PSG)
Measured: 6 months post-surgery
Change in REM Apnea-Hypopnea Index (REM AHI)
As measured in clinical polysomnography (PSG)
Measured: 6 months post-surgery
Change in Minimum Oxygen Saturation (Min SpO2)
As measured in clinical polysomnography (PSG)
Measured: 6 months post-surgery
Change in Mean End Tidal CO2 (ETCO2)
As measured in clinical polysomnography (PSG)
Measured: 6 months post-surgery
Change in Max End Tidal CO2 (ETCO2)
As measured in clinical polysomnography (PSG)
Measured: 6 months post-surgery
Change in Oxyhemoglobin desaturation ≥3% Index (ODI)
As measured in clinical polysomnography (PSG)
Measured: 6 months post-surgery
Change in % Total Sleep Time with ETCO2 > 45/50 mmHg
As measured in clinical polysomnography (PSG)
Measured: 6 months post-surgery
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Dec 2021
- Study start9 Nov 2021
- Primary completion11 Oct 2024
- Study completion11 Oct 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obstructive Sleep Apnea of ChildStudies of the same condition, open and under way.
- More trials run by Oregon Health and Science UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 30 participants (actual)
Sponsor and investigators
- Lead sponsor
- Oregon Health and Science University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Derek Lam, MD, MPH, Oregon Health and Science University
- Investigators
- Derek J Lam, MD, Principal investigator, Oregon Health and Science University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05154214
- Sponsor's protocol ID
- STUDY00023287
- Status last verified
- Sep 2025
- First submitted
- 15 Nov 2021
- Last updated
- 29 Sep 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 29 Sep 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Prospective Study of Surgical Treatment of Children With Obstructive Sleep Apnea and Small Tonsils or Down Syndrome
- ClinicalTrials.gov ID
- NCT05154214
- Acronym / sponsor ID
- STUDY00023287
- Conditions
- Obstructive Sleep Apnea of Child
- Keywords
- Adenotonsillectomy, Drug-induced sleep endoscopy, pediatric, otolaryngology, OSA, sleep apnea, Down Syndrome
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 30 participants (actual)
- Lead sponsor
- Oregon Health and Science UniversityUniversity, hospital or other
- Study start
- 9 Nov 2021 (actual)
- Primary completion
- 11 Oct 2024 (actual)
- Study completion
- 11 Oct 2024 (actual)
- First posted
- 13 Dec 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to prospectively compare the effectiveness of a novel personalized approach to the surgical treatment of obstructive sleep apnea (OSA) in children, drug induced sleep endoscopy (DISE) directed surgery versus the standard adenotonsillectomy (AT). This will also serve to test the feasibility of recruiting families for a future randomized protocol comparing the same surgical techniques. It is the investigators' central hypothesis that a personalized DISE-directed surgical approach that uses existing procedures to address the specific fixed and dynamic anatomic features causing obstruction (ie, anatomic endotypes) in each child with small tonsils or Down syndrome will be superior to the currently recommended standard first line approach of AT. This novel approach may improve OSA outcomes and reduce the burden of unnecessary AT or secondary surgery for persistent OSA after an ineffective AT. To test this hypothesis, the investigators will study children aged 2 to 18 years with clinically small tonsils (Brodsky score 1+ or 2+ on a scale 1+ to 4+) OR Down syndrome.
Detailed description
Obstructive sleep apnea (OSA) is defined as repetitive obstruction of the upper airway during sleep and has been estimated to affect 1-6% of the general pediatric population. Untreated OSA in children has been associated with childhood hypertension, autonomic dysfunction, attention-deficit/hyperactivity disorder, neurobehavioral impairment, and poor quality of life. These sequelae contribute to a 226% increase in health care utilization among children with OSA compared to controls, primarily in the form of increased hospitalizations, emergency department visits, and medication use. Adenotonsillar hypertrophy is considered the most common risk factor for OSA in children, and adenotonsillectomy (AT) is the first line treatment.
Although AT is the recommended first line treatment for pediatric OSA in treatment guidelines, multiple studies have demonstrated that AT is not always curative, with estimates of persistent OSA after AT ranging from 25 to 75%. Many risk factors for AT failure have been reported, but the impact of tonsil size on AT outcome remains a controversial topic. Not every child with enlarged tonsils will have OSA, and conversely, there are many children with proven OSA who do not have clinically large tonsils or adenoids. The prevalence of small tonsils (1+ or 2+ on Brodsky tonsil scoring scale of 1+ to 4+) has been reported to be 67-70% among children with symptoms of OSA presenting to either the emergency department or a pediatric pulmonology clinic. Clinic assessment of tonsil size during an awake examination has not consistently correlated with either baseline disease severity or response to AT. The outcome of AT in children with small tonsils (Brodsky 1+ or 2+) remains unknown and clinical decisions in children with small tonsils are not evidence-based.
Patients with Down Syndrome have a higher incidence of OSA than the general pediatric population, with rates of 30-60%, resulting in increased morbidity and decreased quality of life for affected individuals. Children with Down Syndrome often undergo T\&A for obstructive sleep apnea; however 30-50% will have persistent obstructive sleep patterns requiring continuous positive pressure airway support (CPAP) or tracheotomy. Persistent obstruction is attributed to anatomic and physiologic differences in this population, including reduced muscular tone, macroglossia, maxillary hypoplasia, and lingual tonsil hypertrophy.
Drug-induced sleep endoscopy (DISE) enables direct observation of the sites and patterns of obstruction during sedated sleep. DISE increasingly helps guide surgical decision-making in adult OSA, and the investigators hypothesize DISE can guide surgical decisions in pediatric OSA and improve outcomes. Towards that end, the study team has developed and validated the DISE Rating Scale in children. Furthermore, the investigators have demonstrated DISE ratings of adenotonsillar obstruction during sedated sleep are strongly associated with both OSA severity and response to AT, unlike clinic assessments of tonsil size. This preliminary data and others' studies have identified non-adenotonsillar obstruction can also occur at the nose, palate, base of tongue, and larynx. DISE findings in surgically naïve children and the outcomes of procedures based on those findings have been reported in mostly small observational case series. The surgical plan may be modified from the standard AT in up to 77% of children based on DISE findings. These alternative procedures can be less invasive (e.g., only isolated adenoidectomy or isolated tonsillectomy) or include procedures to address other anatomic sites in addition to or instead of the tonsils and adenoids. The most commonly reported non-adenotonsillar sites of obstruction are the nose, velopharynx (soft palate), tongue base, and the larynx. DISE-directed surgery at these sites may improve pediatric OSA outcomes, but existing studies are small, uncontrolled case series in heterogeneous study populations. There are no trials directly comparing AT and DISE-directed surgery in the common scenario of surgically naïve children with small tonsils. This study will inform a future randomized trial that has the potential to change the paradigm of treating OSA in children with small tonsils or Down syndrome, thereby improving outcomes, and reducing inappropriate AT and need for secondary sleep surgery.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Adenotonsillectomy | – | Procedure: AdenotonsillectomyExcision of the palatine tonsils and excision or ablation of the adenoids by each individual surgeon's preferred techniques. |
| Drug-induced sleep endoscopy directed surgery (DISE) | – | Procedure: Drug-induced sleep endoscopy directed surgeryDISE will be performed by the surgeon performing the surgical intervention. The DISE Rating Scale assesses the degree of maximal closure or obstruction at six locations in the upper airway: the nose, nasopharynx (adenoids), velopharynx (soft palate), oropharynx (tonsils), tongue base (tongue, lingual tonsils), and larynx (epiglottis, arytenoids). The degree of obstruction is scored on a 3-point rating scale as none (0), partial (+1), or complete (+2) at each anatomic site. The rating at each anatomic level can be summed into a DISE Rating Scale total. The actual surgery performed will determine which established surgical treatments will be used based on the results of the DISE. |
Who may qualify
- Ages
- 2 to 18 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult
- Study population
- Participants will be recruited from the Oregon Health and Science University pediatric otolaryngology clinic and from the pediatric sleep medicine clinic.
Key inclusion criteria (4 listed)
- Moderate OSA (oAHI ≥ 5),
- Clinically small tonsils (Brodsky score 1+ or 2+) AND/OR Down syndrome
- Desiring surgical treatment.
- English or Spanish speaking
Key exclusion criteria (1 listed)
- Non-Down Syndrome neuromuscular disorder, craniofacial anomaly, genetic abnormality, subglottic or tracheal stenosis, tracheostomy dependence.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| AdenotonsillectomyRemoval of tonsils and adenoids | Procedure or surgery | Adenotonsillectomy |
| Drug-induced sleep endoscopy directed surgerySurgeries selected based on direct visualization of airway collapse using endoscopy during drug-induced sleep | Procedure or surgery | Drug-induced sleep endoscopy directed surgery (DISE) |
Primary outcome
Change in Pediatric Quality of Life (PedsQL), a generic quality of life scale
Time frame: 6 months post-surgery
Parent and child-reported surveys, higher scores indicate better quality of life, mean scores 0-100
Parent-reported ease of participation
Time frame: 6 months post-surgery
Parent-reported survey or parent interview
Parent-reported barriers to recruitment
Time frame: Initial visit
Parent-reported survey or parent interview
Change in Obstructive Sleep Apnea -18 (OSA-18): disease-specific quality of life survey
Time frame: 6 months post-surgery
Parent-reported survey, higher scores mean higher disease burden, scores from 18-126
Parent-reported barriers to recruitment
Time frame: 6 months post-surgery
Parent-reported survey or parent interview
8 secondary outcomes
Change in Obstructive Apnea-Hypopnea Index (oAHI)
Time frame: 6 months post-surgery
Change in Total Apnea-Hypopnea Index
Time frame: 6 months post-surgery
Change in REM Apnea-Hypopnea Index (REM AHI)
Time frame: 6 months post-surgery
Change in Minimum Oxygen Saturation (Min SpO2)
Time frame: 6 months post-surgery
Change in Mean End Tidal CO2 (ETCO2)
Time frame: 6 months post-surgery
Change in Max End Tidal CO2 (ETCO2)
Time frame: 6 months post-surgery
Change in Oxyhemoglobin desaturation ≥3% Index (ODI)
Time frame: 6 months post-surgery
Change in % Total Sleep Time with ETCO2 > 45/50 mmHg
Time frame: 6 months post-surgery
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Sep 2025.
- Individual participant dataSharing planned: No
Related trials for Obstructive Sleep Apnea of Child
RecruitingObservational study
Prediction of Tongue Base Obstruction During Sleep
Obstructive Sleep Disordered Breathing
RecruitingObservational study
Characterization of the Tongue in Children With Obstructive Sleep-disordered Breathing
Obstructive Sleep Disordered Breathing
Not yet recruiting
Pediatric/Adolescent WatchPAT 400 Reliability Pilot Study
Pediatric Sleep Disordered Breathing, Obstructive Sleep Apnea
RecruitingObservational study
SUNOSI® (Solriamfetol) Pregnancy Registry
Narcolepsy, Obstructive Sleep Apnea
RecruitingPhase 2
Down Syndrome Obstructive Sleep Apnea
Down Syndrome, Obstructive Sleep Apnea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Derek J Lam, MD principal investigator
Oregon Health and Science University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Obstructive Sleep Apnea of Child, run by Oregon Health and Science University at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 29 Sep 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Pediatric Quality of Life (PedsQL), a generic quality of life scale (time frame: 6 months post-surgery). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Sep 2025.